Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 2Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 37Neoplasm Metastasis 6Neoplasms 3Ovarian Neoplasms 2Hereditary Sensory and Autonomic Neuropathies 2Endometrial Neoplasms 2Carcinoma, Ovarian Epithelial 2Breast Neoplasms, Male 2Breast Diseases 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Neoplasms by Site 1Medulloblastoma 1Lung Neoplasms 1Locoregional Recurrence 1Locally Advanced (Inoperable) or Metastatic Breast Cancer 1Head and Neck Neoplasms 1HR+/HER2- Breast Cancer 1HER2 Negative Breast Cancer 1Glioma 1Glioblastoma 1Fallopian Tube Neoplasms 1Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer 1ER+ HER2- Advanced Breast Cancer 1Digestive System Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

ribociclib 2exemestane 2abemaciclib 2Tamoxifen 2Letrozole 2Anastrozole 2palbociclib 1elacestrant 1acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1Standard of Care 1Practice Guidelines as Topic 1Methods 1Leuprolide 1Interviews as Topic 1Goserelin 1Genetic Counseling 1Educational Status 1Early Intervention, Educational 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Breast Neoplasms, Male × ribociclib × Clear all
NCT05827081 2026-06-03

Adjuvant WIDER

Novartis

Phase 3 Recruiting
1,400 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT06805812 2025-02-03

PALMARES-2

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Recruiting
3,500 enrolled
Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡